Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00268_DB01267_nanopub.RA_j9A7DvKQYG9NLmtWY1kFFClqAHg6Jl6vVglEWvurP0#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00268_DB01267 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00268_DB01267 label "DDI between Ropinirole and Paliperidone - The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, ropinirole. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. [drugbank_resource:DB00268_DB01267]" assertion.
- drugbank_resource:DB00268_DB01267 identifier "drugbank_resource:DB00268_DB01267" assertion.
- drugbank_resource:DB00268_DB01267 title "DDI between Ropinirole and Paliperidone - The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, ropinirole. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary." assertion.
- drugbank:DB01267 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00268_DB01267 assertion.
- drugbank:DB00268 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00268_DB01267 assertion.